383 related articles for article (PubMed ID: 21623211)
1. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
Voth M; Rosenberg M; Breuer J
Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
[TBL] [Abstract][Full Text] [Related]
2. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
Shellock FG; Parker JR; Venetianer C; Pirovano G; Spinazzi A
Invest Radiol; 2006 Jun; 41(6):500-9. PubMed ID: 16763468
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
[TBL] [Abstract][Full Text] [Related]
4. Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications.
Endrikat J; Vogtlaender K; Dohanish S; Balzer T; Breuer J
Invest Radiol; 2016 Sep; 51(9):537-43. PubMed ID: 26964075
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients.
Schieren G; Tokmak F; Lefringhausen L; van Bracht M; Perings C; Willers R; Günsel A; Kemper F; Wiesmüller GA; Rump LC
Am J Kidney Dis; 2008 Jun; 51(6):976-86. PubMed ID: 18501785
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
7. Gadobutrol for contrast-enhanced magnetic resonance imaging in elderly patients: review of the safety profile from clinical trial, post-marketing surveillance, and pharmacovigilance data.
Endrikat J; Schwenke C; Prince MR
Clin Radiol; 2015 Jul; 70(7):743-51. PubMed ID: 25933719
[TBL] [Abstract][Full Text] [Related]
8. Safety of gadobutrol in more than 1,000 pediatric patients: subanalysis of the GARDIAN study, a global multicenter prospective non-interventional study.
Glutig K; Bhargava R; Hahn G; Hirsch W; Kunze C; Mentzel HJ; Schaefer JF; Willinek W; Palkowitsch P;
Pediatr Radiol; 2016 Aug; 46(9):1317-23. PubMed ID: 27041276
[TBL] [Abstract][Full Text] [Related]
9. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Safety of Macrocyclic Gadobutrol in Children Aged Younger Than 2 Years Including Term Newborns in Comparison to Older Populations.
Kunze C; Mentzel HJ; Krishnamurthy R; Fleck R; Stenzel M; Bhargava R; Burrowes D; Sutter G; Schultze-Mosgau M; Santiuste M; Hahn G
Invest Radiol; 2016 Jan; 51(1):50-7. PubMed ID: 26340504
[TBL] [Abstract][Full Text] [Related]
12. Toxicological safety evaluation of gadobutrol.
Wack C; Steger-Hartmann T; Mylecraine L; Hofmeister R
Invest Radiol; 2012 Nov; 47(11):611-23. PubMed ID: 23011188
[TBL] [Abstract][Full Text] [Related]
13. Safety of gadoxetate disodium: Results from the clinical phase II-III development program and postmarketing surveillance.
Endrikat JS; Dohanish S; Balzer T; Breuer JA
J Magn Reson Imaging; 2015 Sep; 42(3):634-43. PubMed ID: 25643844
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].
Vogl TJ; Friebe CE; Balzer T; Mack MG; Steiner S; Schedel H; Pegios W; Lanksch W; Banzer D; Felix R
Radiologe; 1995 Aug; 35(8):508-16. PubMed ID: 7568795
[TBL] [Abstract][Full Text] [Related]
15. Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.
de Kerviler E; Maravilla K; Meder JF; Naggara O; Dubourdieu C; Jullien V; Desché P
Invest Radiol; 2016 Sep; 51(9):544-51. PubMed ID: 27504794
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of acute adverse reactions to gadobutrol--a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials.
Forsting M; Palkowitsch P
Eur J Radiol; 2010 Jun; 74(3):e186-92. PubMed ID: 19574008
[TBL] [Abstract][Full Text] [Related]
17. [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
Herborn CU; Jäger-Booth I; Lodemann KP; Spinazzi A; Goyen M
Rofo; 2009 Jul; 181(7):652-7. PubMed ID: 19291607
[TBL] [Abstract][Full Text] [Related]
18. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
Ball P; Mandell L; Patou G; Dankner W; Tillotson G
Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
[TBL] [Abstract][Full Text] [Related]
19. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
Lode H; Vogel F; Elies W
Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T.
Morelli JN; Runge VM; Vu L; Loynachan AT; Attenberger UI
Invest Radiol; 2010 Dec; 45(12):810-8. PubMed ID: 20856127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]